Company news

Neurizon Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

European Patent relating to MPL Combinations in Cancer

February 27, 2023

First Patient of Cohort 2 Dosed in MND Trial

February 19, 2023

PharmAust canine trial update

February 9, 2023

PharmAust Progresses to Elevated Doses in MND Patients

January 19, 2023

MND Trial Successfully Completes First Patient Cohort

January 5, 2023

PharmAust Canine Trial Update clarification

December 20, 2022

PharmAust Canine Trial Update

December 19, 2022

MND Trial Completes Enrolment of First Patient Cohort

December 1, 2022

DNDi contract extension for PharmAust subsidiary Epichem

November 3, 2022

First Patient Dosed in MND Phase 1/2 Trial

October 2, 2022

First Patient in US Canine Cancer Trials Begins Treatment

September 6, 2022

Update on PharmAust Canine Cancer Trials

August 17, 2022

PharmAust Clinical Trials Update

May 23, 2022

PharmAust receives $210k prepayment of forecast R&D rebate

May 17, 2022

MPL tablets arrive in Melbourne for MND Clinical Trial

May 15, 2022

PharmAust Expands Lymphoma Canine Trial to the USA

May 10, 2022

PharmAust Receives $708k R&D Tax Incentive Refund

April 18, 2022

PAA appoints trial manager & receives $200k from FightMND

April 7, 2022

MPL manufactured and tableting commenced

March 14, 2022

Preliminary MPL antiviral leukaemia preclinical WEHI results

February 23, 2022

Key Appointment to Progress MPL COVID-19 Clinical Trial

February 20, 2022

Appendix 4D & Half Year Report

February 18, 2022

Epichem Confirms Effectiveness of OHD E-Waste Project

February 15, 2022

Update on Manufacture of MPL & Tablets for Clinical Trials

February 1, 2022

Epichem Awarded Contract Extension from DNDi

December 14, 2021

Shareholder Update - Progress and Strategy

December 12, 2021

Demonstration batch of smaller size MPL tablets completed

November 30, 2021

MND & COVID-19 Phase 1 Clinical Trials On-Track

November 16, 2021

Canine phase 2b cancer trial expands to New Zealand

November 14, 2021

MPL Manufacturing and Human Trials Update

October 20, 2021

Following Extension of Survival, PAA Prepares Phase 3 Trial

October 17, 2021

Prospectus

October 1, 2021

Entitlement Options Offer

October 1, 2021

Epichem Completes Final Loan Repayment

August 30, 2021

Epichem Completes Build of OHD Benchtop Flow Reactor

August 2, 2021

Monepantel and monepantel sulfone COVID-19 anti-viral update

July 26, 2021

PharmAust and WEHI to Investigate HTLV-1 Viral Infections

July 11, 2021

Phase IIb Dog Trial Achieves Interim Clinical Endpoints

June 27, 2021

PharmAust receives ethics approval for Phase I trial in MND

June 1, 2021

Phase IIb Canine Trial Identifies Therapeutic Window for MPL

April 26, 2021

PharmAust Receives $750k R&D Tax Incentive Refund

April 7, 2021

Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity

April 6, 2021

Update on Phase IIb Clinical Trial of Monepantel in Pet Dogs

March 29, 2021

Licensing Agreement to Develop Waste to Fuels Technology

March 22, 2021

Update on Phase IIb Clinical Trial recruitment

February 14, 2021

Epichem Awarded $200K WasteSorted e-Waste Grant

January 21, 2021

Leiden University Medical Centre Monepantel COVID-19 Testing

January 7, 2021

PAA & ONJCRI to Continue MPL Pre-clinical Investigations

January 4, 2021

PAA Commences Manufacture of GMP-Grade MPL for Human Trials

December 22, 2020

PharmAust to Commence Phase IIb Dog Cancer Trial

December 21, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 36 decks. Every deck is listed under its year.